10-K: AEON Biopharma's 10-K Filing Reveals Strategic Shift to Biosimilar Pathway, Cites Going Concern Uncertainty

Sentiment:

Annual Report 24 March 2025 4:07 PM

AEON Biopharma's latest 10-K filing highlights a strategic pivot towards a biosimilar regulatory pathway for ABP-450, while also acknowledging substantial doubt about the company's ability to continue as a going concern due to ongoing losses and the need for additional financing.

Capital raiseThe company will need to raise additional capital to fund its operations.The company is actively attempting to secure additional capital to fund its operations.The company may sell common stock, convertible securities or other equity securities in one or more transactions at a price per share that is less than the price per share paid by current stockholders.

Worse than expectedThe company has concluded that it does not have sufficient cash to fund its operations and to meet its obligations as they become due within one year from the date that its consolidated financial statements are issued and as a result, there is substantial doubt about its ability to continue as a going concern.

Summary

AEON Biopharma is now focusing on developing ABP-450 as a biosimilar to Botox, targeting a $4.4 billion market by 2027.
The company discontinued Phase 2 clinical trials for episodic and chronic migraine due to unmet primary endpoints and implemented cash preservation measures.
AEON held an initial meeting with the FDA in the third quarter of 2024 and commenced analytical studies in the fourth quarter of 2024 to prepare for a potential Biosimilar Biological Product Development (BPD) Type 2a meeting with the FDA in the second half of 2025.
The company reported a net income of $42.0 million for the year ended December 31, 2024, mainly due to gain on fair value of contingent consideration, and net losses of $60.7 million and $324.0 million for the periods from January 1, 2023 to July 21, 2023 (Predecessor) and July 22, 2023 to December 31, 2023 (Successor), respectively.
As of December 31, 2024, AEON had $13 thousand in cash and cash equivalents and an accumulated deficit of $431.6 million, raising substantial doubt about its ability to continue as a going concern.
AEON expects to have sufficient cash to fund its operating plan into the fourth quarter of 2025, including $18.3 million in net proceeds related to a public offering in January 2025.
The company is actively attempting to secure additional capital to fund its operations.
A lawsuit filed by Odeon Capital Group LLC is ongoing, with each party filing a summary judgment motion in March 2025.
The company received a notice from the NYSE American regarding non-compliance with continued listing standards due to stockholders' equity being below $2.0 million.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there's a strategic shift and some positive financial adjustments, the going concern warning and dependence on future capital raises weigh heavily, indicating a cautious outlook.

Positives

The company is actively attempting to secure additional capital to fund its operations.
The company reported a net income of $42.0 million for the year ended December 31, 2024, mainly due to gain on fair value of contingent consideration.
The company expects to have sufficient cash to fund its operating plan into the fourth quarter of 2025, including $18.3 million in net proceeds related to a public offering in January 2025.

Negatives

Phase 2 clinical trials for episodic and chronic migraine were discontinued due to failure to meet primary endpoints.
As of December 31, 2024, AEON had $13 thousand in cash and cash equivalents and an accumulated deficit of $431.6 million, raising substantial doubt about its ability to continue as a going concern.
The company received a notice from the NYSE American regarding non-compliance with continued listing standards due to stockholders' equity being below $2.0 million.

Risks

The company's future success depends on the successful and timely regulatory approval and commercialization of ABP-450.
The company may not be able to raise additional capital on commercially reasonable terms or at all.
The company faces significant competition in the pharmaceutical industry.
The company is subject to extensive government regulation.
The price of the company's common stock may be volatile.
Sales of a substantial number of the company's securities in the public market could cause the price of the company's common stock and warrants to fall.
The company relies on the Daewoong Agreement to provide exclusive rights to commercialize and distribute ABP-450 in certain territories, and any termination or loss of significant rights would materially and adversely affect the company.
The company currently relies solely on Daewoong to manufacture ABP-450, and any production or other problems with Daewoong could adversely affect the company.
Third-party claims of intellectual property infringement may prevent or delay the company's development and commercialization efforts.

Future Outlook

AEON expects to continue to incur significant expenses and increasing net operating losses for the foreseeable future as it seeks regulatory approval and prepares for potential commercialization of ABP-450.

Management Comments

Management has concluded that substantial doubt about our ability to continue as a going concern exists.
We will actively attempt to secure additional capital to fund our operations.

Industry Context

The global therapeutic botulinum toxin market is expected to grow from $3.0 billion in 2020 to an estimated $4.4 billion in 2027. AEON is positioning itself to compete in this market with ABP-450 as a biosimilar to Botox.

Comparison to Industry Standards

Botox, Dysport and Xeomin collectively made up over 98% of the United States therapeutic market for botulinum toxins in 2021.
The market leader for therapeutic botulinum toxins is Botox, which is marketed by AbbVie Inc., or AbbVie, and had approximately 85% of the global therapeutic market share for botulinum toxins and 95% of the United States therapeutic market share for botulinum toxins in 2019.
The migraine indication is AbbVies single largest toxin therapeutic indication and contributes to 45% of AbbVies therapeutic toxin sales.
The main approved competitors to Botox are Dysport, marketed by Ipsen Ltd., and Xeomin, marketed by Merz Pharmaceuticals, LLC, each of which have approximately 2% of the global market share for therapeutic botulinum toxin treatments.

Legal Proceedings

Odeon Capital Group LLC filed a lawsuit against the Company in the Supreme Court of the State of New York, alleging that the Company failed to pay Odeons deferred underwriting fee of $1.25 million.
Odeons breach of contract claim is proceeding, with each party filing a summary judgment motion in March 2025, which the court is expected to decide upon in the coming months.

Stakeholder Impact

Shareholders face potential dilution from future equity issuances.
Employees may be affected by potential cost-cutting measures or changes in strategic direction.
Customers (potential patients) may experience delays in the availability of ABP-450 if development is hindered by financial constraints.
Suppliers and creditors face increased risk due to the company's going concern uncertainty.

Next Steps

The company will prepare for a potential Biosimilar Biological Product Development (BPD) Type 2a meeting with the FDA in the second half of 2025 to review the results from the studies.
The company intends to consider available options to resolve the non-compliance with the Minimum Requirement by August 3, 2026.

Key Dates

Date	Description
December 12, 2022	Old AEON and Priveterra entered into a Business Combination Agreement.
April 27, 2023	Amendment No. 1 to Business Combination Agreement.
July 21, 2023	The parties consummated the transactions contemplated by the Business Combination Agreement (collectively referred to as the Merger).
July 24, 2023	The post-Merger Company common stock and warrants commenced trading on the NYSE American under the symbols AEON and AEON WS, respectively.
September 18, 2023	Odeon Capital Group LLC filed a lawsuit against the Company.
March 19, 2024	The Company entered into a subscription agreement with Daewoong relating to the sale and issuance by the Company of senior secured convertible notes.
March 24, 2024	The Company issued and sold to Daewoong one Convertible Note in the principal amount of $5.0 million.
April 12, 2024	The Company issued and sold to Daewoong one Convertible Note in the principal amount of $10.0 million.
May 16, 2024	The company announced the discontinuation of its Phase 2 clinical trials for episodic and chronic migraine in order to implement certain cash preservation measures.
July 9, 2024	The company announced a strategic reprioritization to pursue a 351(k) biosimilar regulatory pathway for ABP-450, using AbbVie Inc.s product Botox as a proposed reference product.
January 6, 2025	The Company entered into an underwriting agreement with Aegis Capital Corp. for a public offering.
January 7, 2025	The closing of the Offering occurred.
February 3, 2025	The Company received a written notice of non-compliance from the NYSE American LLC.
February 24, 2025	The Board approved the filing of a Certificate of Amendment to the Certificate of Incorporation to effect a reverse stock split.
February 26, 2025	The effective date of the Reverse Stock Split.
March 5, 2025	The Company must submit a plan advising of actions taken or will be taken to regain compliance with the continued listings standards of the Company Guide.
March 21, 2025	As of this date, there were 10,532,802 of the registrants shares of Class A common stock outstanding.
August 3, 2026	If the Company does not make progress consistent with the Plan, then the NYSE American will initiate delisting proceedings as appropriate.

Keywords

ABP-450, biosimilar, Botox, clinical trials, regulatory approval, Daewoong, migraine, cervical dystonia, financial results, going concern, capital raise, biopharmaceutical

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.